{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T06:00:00Z","timestamp":1771740000775,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06304-5","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T05:18:38Z","timestamp":1771737518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive models for biopsy upgrading in active surveillance for prostate cancer: a scoping review"],"prefix":"10.1007","volume":"44","author":[{"given":"Aurora J.","family":"Grutman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aidan S.","family":"Weitzner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa G.","family":"Arbuiso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack A.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian P.","family":"Pavlovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,22]]},"reference":[{"issue":"1","key":"6304_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JU.0000000000002758","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA et al (2022) Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up. J Urol 208(1):19\u201325. https:\/\/doi.org\/10.1097\/JU.0000000000002758","journal-title":"J Urol"},{"issue":"6","key":"6304_CR2","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.21037\/tau-20-1370","volume":"10","author":"DK Shill","year":"2021","unstructured":"Shill DK, Roobol MJ, Ehdaie B, Vickers AJ, Carlsson SV (2021) Active surveillance for prostate cancer. Transl Androl Urol 10(6):2809\u20132819. https:\/\/doi.org\/10.21037\/tau-20-1370","journal-title":"Transl Androl Urol"},{"issue":"2","key":"6304_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.21037\/tau.2018.03.02","volume":"7","author":"M Komisarenko","year":"2018","unstructured":"Komisarenko M, Martin LJ, Finelli A (2018) Active surveillance review: contemporary selection criteria, follow-up, compliance and outcomes. Transl Androl Urol 7(2):243\u2013255. https:\/\/doi.org\/10.21037\/tau.2018.03.02","journal-title":"Transl Androl Urol"},{"issue":"1","key":"6304_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamainternmed.2024.5994","volume":"185","author":"TJ Daskivich","year":"2025","unstructured":"Daskivich TJ, Luu M, Heard J, Thomas IC, Leppert JT (2025) Overtreatment of Prostate Cancer Among Men With Limited Longevity in the Active Surveillance Era. JAMA Intern Med 185(1):28. https:\/\/doi.org\/10.1001\/jamainternmed.2024.5994","journal-title":"JAMA Intern Med"},{"issue":"3","key":"6304_CR5","doi-asserted-by":"publisher","first-page":"e231439","DOI":"10.1001\/jamanetworkopen.2023.1439","volume":"6","author":"MR Cooperberg","year":"2023","unstructured":"Cooperberg MR, Meeks W, Fang R, Gaylis FD, Catalona WJ, Makarov DV (2023) Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US. JAMA Netw Open 6(3):e231439. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.1439","journal-title":"JAMA Netw Open"},{"key":"6304_CR6","doi-asserted-by":"publisher","unstructured":"Patel NA, Barocas DA, Lin DW et al (2025) Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group. JAMA Oncol Published online July 31. https:\/\/doi.org\/10.1001\/jamaoncol.2025.2304","DOI":"10.1001\/jamaoncol.2025.2304"},{"issue":"1","key":"6304_CR7","doi-asserted-by":"publisher","first-page":"e2454366","DOI":"10.1001\/jamanetworkopen.2024.54366","volume":"8","author":"II De Vos","year":"2025","unstructured":"De Vos II, Nieboer D, Frydenberg M et al (2025) Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active Surveillance. JAMA Netw Open 8(1):e2454366. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.54366","journal-title":"JAMA Netw Open"},{"issue":"5","key":"6304_CR8","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.juro.2011.12.082","volume":"187","author":"V Iremashvili","year":"2012","unstructured":"Iremashvili V, Soloway MS, Rosenberg DL, Manoharan M (2012) Clinical and Demographic Characteristics Associated With Prostate Cancer Progression in Patients on Active Surveillance. J Urol 187(5):1594\u20131600. https:\/\/doi.org\/10.1016\/j.juro.2011.12.082","journal-title":"J Urol"},{"issue":"1","key":"6304_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/bju.12112","volume":"112","author":"V Iremashvili","year":"2013","unstructured":"Iremashvili V, Burdick-Will J, Soloway MS (2013) Improving risk stratification in patients with prostate cancer managed by active surveillance: a nomogram predicting the risk of biopsy progression. BJU Int 112(1):39\u201344. https:\/\/doi.org\/10.1111\/bju.12112","journal-title":"BJU Int"},{"issue":"6","key":"6304_CR10","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.eururo.2015.03.023","volume":"68","author":"DP Ankerst","year":"2015","unstructured":"Ankerst DP, Xia J, Thompson IM et al (2015) Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary\u2013Early Detection Research Network Active Surveillance Biopsy Risk Calculator. Eur Urol 68(6):1083\u20131088. https:\/\/doi.org\/10.1016\/j.eururo.2015.03.023","journal-title":"Eur Urol"},{"issue":"1","key":"6304_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.juro.2015.01.102","volume":"194","author":"S Jain","year":"2015","unstructured":"Jain S, Loblaw A, Vesprini D et al (2015) Gleason Upgrading with Time in a Large Prostate Cancer Active Surveillance Cohort. J Urol 194(1):79\u201384. https:\/\/doi.org\/10.1016\/j.juro.2015.01.102","journal-title":"J Urol"},{"issue":"5","key":"6304_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00345-016-1933-0","volume":"35","author":"ML Blute","year":"2017","unstructured":"Blute ML, Shiau JM, Truong M et al (2017) A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer. World J Urol 35(5):729\u2013735. https:\/\/doi.org\/10.1007\/s00345-016-1933-0","journal-title":"World J Urol"},{"issue":"65","key":"6304_CR13","doi-asserted-by":"publisher","first-page":"108451","DOI":"10.18632\/oncotarget.21984","volume":"8","author":"\u00c1 Borque-Fernando","year":"2017","unstructured":"Borque-Fernando \u00c1, Esteban LM, Collado-Serra A et al (2017) The management of active surveillance in prostate cancer: validation of the Canary Prostate Active Surveillance Study risk calculator with the Spanish Urological Association Registry. Oncotarget 8(65):108451\u2013108462. https:\/\/doi.org\/10.18632\/oncotarget.21984","journal-title":"Oncotarget"},{"issue":"3","key":"6304_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.eururo.2016.11.017","volume":"72","author":"DW Lin","year":"2017","unstructured":"Lin DW, Newcomb LF, Brown MD et al (2017) Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. Eur Urol 72(3):448\u2013454. https:\/\/doi.org\/10.1016\/j.eururo.2016.11.017","journal-title":"Eur Urol"},{"issue":"1","key":"6304_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bju.13608","volume":"120","author":"MM Mamawala","year":"2017","unstructured":"Mamawala MM, Rao K, Landis P et al (2017) Risk prediction tool for grade re-classification in men with favourable\u2010risk prostate cancer on active surveillance. BJU Int 120(1):25\u201331. https:\/\/doi.org\/10.1111\/bju.13608","journal-title":"BJU Int"},{"issue":"2","key":"6304_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.eururo.2018.01.017","volume":"74","author":"MR Cooperberg","year":"2018","unstructured":"Cooperberg MR, Brooks JD, Faino AV et al (2018) Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. Eur Urol 74(2):211\u2013217. https:\/\/doi.org\/10.1016\/j.eururo.2018.01.017","journal-title":"Eur Urol"},{"issue":"6","key":"6304_CR17","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.juro.2017.12.006","volume":"199","author":"RSC Liu","year":"2018","unstructured":"Liu RSC, Olkhov-Mitsel E, Jeyapala R et al (2018) Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance. J Urol 199(6):1475\u20131481. https:\/\/doi.org\/10.1016\/j.juro.2017.12.006","journal-title":"J Urol"},{"issue":"4","key":"6304_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/bju.14811","volume":"124","author":"SP Connell","year":"2019","unstructured":"Connell SP, Yazbek-Hanna M, McCarthy F et al (2019) A four\u2010group urine risk classifier for predicting outcomes in patients with prostate cancer. BJU Int 124(4):609\u2013620. https:\/\/doi.org\/10.1111\/bju.14811","journal-title":"BJU Int"},{"issue":"3","key":"6304_CR19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41391-018-0124-z","volume":"22","author":"LF Newcomb","year":"2019","unstructured":"Newcomb LF, Zheng Y, Faino AV et al (2019) Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer Prostatic Dis 22(3):438\u2013445. https:\/\/doi.org\/10.1038\/s41391-018-0124-z","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"9","key":"6304_CR20","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.3390\/cancers12092708","volume":"12","author":"S Chandramouli","year":"2020","unstructured":"Chandramouli S, Leo P, Lee G et al (2020) Computer Extracted Features from Initial H&E Tissue Biopsies Predict Disease Progression for Prostate Cancer Patients on Active Surveillance. Cancers 12(9):2708. https:\/\/doi.org\/10.3390\/cancers12092708","journal-title":"Cancers"},{"issue":"10","key":"6304_CR21","doi-asserted-by":"publisher","first-page":"e203187","DOI":"10.1001\/jamaoncol.2020.3187","volume":"6","author":"MR Cooperberg","year":"2020","unstructured":"Cooperberg MR, Zheng Y, Faino AV et al (2020) Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. JAMA Oncol 6(10):e203187. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3187","journal-title":"JAMA Oncol"},{"issue":"4","key":"6304_CR22","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2214\/AJR.19.22196","volume":"214","author":"SH Kim","year":"2020","unstructured":"Kim SH (2020) Development and External Validation of Multiparametric MRI-Derived Nomogram to Predict Risk of Pathologic Upgrade in Patients on Active Surveillance for Prostate Cancer. Am J Roentgenol 214(4):825\u2013834. https:\/\/doi.org\/10.2214\/AJR.19.22196","journal-title":"Am J Roentgenol"},{"issue":"4","key":"6304_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.prnil.2020.05.003","volume":"8","author":"M Roscigno","year":"2020","unstructured":"Roscigno M, Stabile A, Lughezzani G et al (2020) Multiparametric magnetic resonance imaging and clinical variables: Which is the best combination to predict reclassification in active surveillance patients? Prostate Int 8(4):167\u2013172. https:\/\/doi.org\/10.1016\/j.prnil.2020.05.003","journal-title":"Prostate Int"},{"issue":"10","key":"6304_CR24","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.3390\/cancers13102433","volume":"13","author":"P Gandellini","year":"2021","unstructured":"Gandellini P, Ciniselli CM, Rancati T et al (2021) Prediction of Grade Reclassification of Prostate Cancer Patients on Active Surveillance through the Combination of a Three-miRNA Signature and Selected Clinical Variables. Cancers 13(10):2433. https:\/\/doi.org\/10.3390\/cancers13102433","journal-title":"Cancers"},{"issue":"1","key":"6304_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/bju.15136","volume":"127","author":"A Tomer","year":"2021","unstructured":"Tomer A, Nieboer D, Roobol MJ et al (2021) Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. BJU Int 127(1):96\u2013107. https:\/\/doi.org\/10.1111\/bju.15136","journal-title":"BJU Int"},{"issue":"4","key":"6304_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.urolonc.2021.08.007","volume":"40","author":"M Nayan","year":"2022","unstructured":"Nayan M, Salari K, Bozzo A et al (2022) A machine learning approach to predict progression on active surveillance for prostate cancer. Urologic Oncology: Seminars Original Investigations 40(4):161. .e1-161.e7","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"issue":"1","key":"6304_CR27","doi-asserted-by":"publisher","first-page":"12917","DOI":"10.1038\/s41598-021-92341-6","volume":"11","author":"N Sushentsev","year":"2021","unstructured":"Sushentsev N, Rundo L, Blyuss O, Gnanapragasam VJ, Sala E, Barrett T (2021) MRI-derived radiomics model for baseline prediction of prostate cancer progression on active surveillance. Sci Rep 11(1):12917. https:\/\/doi.org\/10.1038\/s41598-021-92341-6","journal-title":"Sci Rep"},{"issue":"1","key":"6304_CR28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41746-022-00659-w","volume":"5","author":"C Lee","year":"2022","unstructured":"Lee C, Light A, Saveliev ES, Van Der Schaar M, Gnanapragasam VJ (2022) Developing machine learning algorithms for dynamic estimation of progression during active surveillance for prostate cancer. npj Digit Med 5(1):110. https:\/\/doi.org\/10.1038\/s41746-022-00659-w","journal-title":"npj Digit Med"},{"key":"6304_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.euros.2022.01.008","volume":"37","author":"BH Press","year":"2022","unstructured":"Press BH, Jones T, Olawoyin O et al (2022) Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer. Eur Urol Open Sci 37:113\u2013119. https:\/\/doi.org\/10.1016\/j.euros.2022.01.008","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"6304_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/jcm12010216","volume":"12","author":"A Light","year":"2022","unstructured":"Light A, Lophatananon A, Keates A et al (2022) Development and External Validation of the STRATified CANcer Surveillance (STRATCANS) Multivariable Model for Predicting Progression in Men with Newly Diagnosed Prostate Cancer Starting Active Surveillance. JCM 12(1):216. https:\/\/doi.org\/10.3390\/jcm12010216","journal-title":"JCM"},{"issue":"10","key":"6304_CR31","doi-asserted-by":"publisher","first-page":"101240","DOI":"10.1016\/j.xcrm.2023.101240","volume":"4","author":"W Tao","year":"2023","unstructured":"Tao W, Wang BY, Luo L et al (2023) A urine extracellular vesicle lncRNA classifier for high-grade prostate cancer and increased risk of progression: A multi-center study. Cell Rep Med 4(10):101240. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101240","journal-title":"Cell Rep Med"},{"issue":"8","key":"6304_CR32","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/pros.24688","volume":"84","author":"SA Fletcher","year":"2024","unstructured":"Fletcher SA, Mamawala MM, Holler AE et al (2024) Cumulative cancer locations on prostate biopsy and active surveillance outcomes in the MRI era. Prostate 84(8):723\u2013730. https:\/\/doi.org\/10.1002\/pros.24688","journal-title":"Prostate"},{"issue":"2","key":"6304_CR33","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jamaoncol.2024.5398","volume":"11","author":"LB Goss","year":"2025","unstructured":"Goss LB, Liu M, Zheng Y et al (2025) Polygenic Risk Score and Upgrading in Patients With Prostate Cancer Receiving Active Surveillance. JAMA Oncol 11(2):168. https:\/\/doi.org\/10.1001\/jamaoncol.2024.5398","journal-title":"JAMA Oncol"},{"issue":"1","key":"6304_CR34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40364-024-00678-7","volume":"12","author":"JR Gregg","year":"2024","unstructured":"Gregg JR, Newcomb L, Wu R et al (2024) Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance. Biomark Res 12(1):134. https:\/\/doi.org\/10.1186\/s40364-024-00678-7","journal-title":"Biomark Res"},{"issue":"4","key":"6304_CR35","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1159\/000444197","volume":"96","author":"GL Almeida","year":"2016","unstructured":"Almeida GL, Petralia G, Ferro M et al (2016) Role of Multi-Parametric Magnetic Resonance Image and PIRADS Score in Patients with Prostate Cancer Eligible for Active Surveillance According PRIAS Criteria. Urol Int 96(4):459\u2013469. https:\/\/doi.org\/10.1159\/000444197","journal-title":"Urol Int"},{"issue":"4","key":"6304_CR36","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.juro.2017.10.010","volume":"199","author":"F Audenet","year":"2018","unstructured":"Audenet F, Vertosick EA, Fine SW et al (2018) Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer. J Urol 199(4):961\u2013968. https:\/\/doi.org\/10.1016\/j.juro.2017.10.010","journal-title":"J Urol"},{"key":"6304_CR37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.euros.2022.05.012","volume":"41","author":"S Remmers","year":"2022","unstructured":"Remmers S, Helleman J, Nieboer D et al (2022) Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative. Eur Urol Open Sci 41:126\u2013133. https:\/\/doi.org\/10.1016\/j.euros.2022.05.012","journal-title":"Eur Urol Open Sci"},{"issue":"8","key":"6304_CR38","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/cncr.32709","volume":"126","author":"ZT Su","year":"2020","unstructured":"Su ZT, Patel HD, Epstein JI, Pavlovich CP, Allaf ME (2020) Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance. Cancer 126(8):1632\u20131639. https:\/\/doi.org\/10.1002\/cncr.32709","journal-title":"Cancer"},{"issue":"1","key":"6304_CR39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.eururo.2016.08.005","volume":"72","author":"RY Coley","year":"2017","unstructured":"Coley RY, Zeger SL, Mamawala M, Pienta KJ, Carter HB (2017) Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer. Eur Urol 72(1):135\u2013141. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.005","journal-title":"Eur Urol"},{"issue":"10","key":"6304_CR40","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1007\/s00345-019-02637-6","volume":"37","author":"B Gershman","year":"2019","unstructured":"Gershman B, Maroni P, Tilburt JC et al (2019) A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. World J Urol 37(10):2099\u20132108. https:\/\/doi.org\/10.1007\/s00345-019-02637-6","journal-title":"World J Urol"},{"issue":"5","key":"6304_CR41","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.eururo.2011.07.039","volume":"60","author":"MJ Roobol","year":"2011","unstructured":"Roobol MJ, Heijnsdijk EAM (2011) Propensity Score Matching, Competing Risk Analysis, and a Competing Risk Nomogram: Some Guidance for Urologists May Be in Place. Eur Urol 60(5):931\u2013933. https:\/\/doi.org\/10.1016\/j.eururo.2011.07.039","journal-title":"Eur Urol"},{"issue":"1","key":"6304_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/JU.0000000000002963","volume":"209","author":"CM De La Calle","year":"2023","unstructured":"De La Calle CM, Mamawala MM, Landis P et al (2023) Clinical Significance of Perineural Invasion in Men With Grade Group 1 Prostate Cancer on Active Surveillance. J Urol 209(1):180\u2013186. https:\/\/doi.org\/10.1097\/JU.0000000000002963","journal-title":"J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06304-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06304-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06304-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T05:18:39Z","timestamp":1771737519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06304-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6304"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06304-5","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,22]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"187"}}